Ripple kopen? Dit zijn de mogelijkheden

Novartis Aandeel

87,76CHF -0,80CHF -0,90%
<
Bedrijf
Kalender
Profiel
>
<
Gerelateerd
Obligaties
>

Novartis AG - Profiel

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Aandeelhouder

Eigenaar in %
Novartis AG9,39
Sandoz Family Foundation3,49
Novartis Foundation For Employee Participation2,57
The Vanguard Group, Inc.2,50
Norges Bank Investment Management2,14
Capital Research & Management Co. (Global Investors)2,03
Wellington Management Co. LLP1,65
UBS AG (Investment Management)1,58
Capital Research & Management Co. (World Investors)1,40
BlackRock Fund Advisors1,21
Zürcher Kantonalbank (Investment Management)0,97
Credit Suisse Asset Management (Schweiz) AG0,82
Dodge & Cox0,63
BlackRock Advisors (UK) Ltd.0,45
JPMorgan Asset Management (UK) Ltd.0,45

Adres

Lichtstrasse 35, 4056 Basel
Postbus:
Telefoon: 41613241111
Fax: 41613248001
Internet: http://www.novartis.com

Management

Bertrand Bodson PhD, MBA
Chief Digital Officer
Klaus Moosmayer, PhD
Chief Ethics Risk & Compliance Officer
Vasant Narasimhan, MD
Chief Executive Officer
Harry Werner Kirsch
Chief Financial Officer
John Tsai, MD
Chief Medical Officer
Elizabeth Theophille
Chief Technology & Digital Officer
Patrice Bula
Director
Mark Levick
Global Head
Paul Barrett
Global Head-External Communications
Lilli Petruzzelli
Global Head-Immuno-Oncology
Samir Shah, MD
Global Head-Investor Relations
Dan Bar-Zohar, MD
Global Head-Neuroscience Development
Stephen Moran, PhD
Global Head-Strategy
Steffen Lang, PhD
Global Head-Technical Operations
Shannon Thyme Klinger, PhD
Group General Counsel
Michael Willi
Group Head-Communications
Samit Hirawat
Head- Global Oncology Development
Mark Never
Head-Cluster Western Europe
Ameet Mallik
Head-Global Marketing, Value & Access
Antonio Ligi
Head-Global Media Relations
Steven Baert, MBA
Head-Human Resources
Natacha Theytaz
Head-Internal Audit
Hans Jörg Reinhardt, PhD
Independent Non-Executive Chairman
William Thomas Winters, MBA
Independent Non-Executive Director
Ann Marie Fudge, MBA
Independent Non-Executive Director
Srikant T. Madhav Datar, PhD
Independent Non-Executive Director
Andreas von Planta, PhD
Independent Non-Executive Director
Ton Büchner, MBA
Independent Non-Executive Director
Mary Elizabeth Doherty
Independent Non-Executive Director
Charles L. Sawyers, MD
Independent Non-Executive Director
Nancy C. Andrews MD, PhD
Independent Non-Executive Director
Frans van Houten
Independent Non-Executive Director
Isabella Zinck
Investor Relations Contact
Pierre-Michel Bringer
Investor Relations Contact
Thomas Hungerbühler
Investor Relations Contact
Janneke van der Kamp
Member Executive Committee
James E. Bradner, MD
Member-Executive Committee
Paul Hudson
Member-Executive Committee
David Lebwohl
SVP & Franchise Global Program Head
Charlotte Pamer-Wieser, PhD
Secretary
Charlie Hough
VP & Global Head-Strategy
Mimi Huizinga, MD
VP & Head-Strategic Data
Enrico Cipro Vanni PhD, MBA
Vice Chairman
Jeffrey Engelman, PhD
Vice President & Global Head-Oncology NIBR

Invoer toevoegen